These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 10338531)
21. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056 [TBL] [Abstract][Full Text] [Related]
22. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013. Quinlan T; Musser KA; Currenti SA; Zansky SM; Halse TA Mol Cell Probes; 2014 Aug; 28(4):138-40. PubMed ID: 24365130 [TBL] [Abstract][Full Text] [Related]
23. Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years. Tsang RS; Shuel M; Jamieson FB; Drews S; Hoang L; Horsman G; Lefebvre B; Desai S; St-Laurent M Int J Infect Dis; 2014 Nov; 28():65-9. PubMed ID: 25244999 [TBL] [Abstract][Full Text] [Related]
24. Pertactin-deficient Bordetella pertussis isolates in Poland-a country with whole-cell pertussis primary vaccination. Polak M; Zasada AA; Mosiej E; Krysztopa-Grzybowska K; Witkowski L; Rzeczkowska M; Piekarska K; Lutyńska A Microbes Infect; 2019; 21(3-4):170-175. PubMed ID: 30580013 [TBL] [Abstract][Full Text] [Related]
25. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209 [TBL] [Abstract][Full Text] [Related]
27. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Gzyl A; Augustynowicz E; Gniadek G; Rabczenko D; Dulny G; Slusarczyk J Vaccine; 2004 Jun; 22(17-18):2122-8. PubMed ID: 15149768 [TBL] [Abstract][Full Text] [Related]
28. Naturally circulating pertactin-deficient Kroes MM; Miranda-Bedate A; Hovingh ES; Jacobi R; Schot C; Pupo E; Raeven RHM; van der Ark AAJ; van Putten JPM; de Wit J; Mariman R; Pinelli E Emerg Microbes Infect; 2021 Dec; 10(1):1358-1368. PubMed ID: 34132167 [TBL] [Abstract][Full Text] [Related]
29. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. Packard ER; Parton R; Coote JG; Fry NK J Med Microbiol; 2004 May; 53(Pt 5):355-365. PubMed ID: 15096543 [TBL] [Abstract][Full Text] [Related]
30. Genome characteristics of Ben Fraj I; Bouchez V; Smaoui H; Kechrid A; Brisse S J Med Microbiol; 2019 Sep; 68(9):1320-1323. PubMed ID: 31329091 [TBL] [Abstract][Full Text] [Related]
31. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. Weber C; Boursaux-Eude C; Coralie G; Caro V; Guiso N J Clin Microbiol; 2001 Dec; 39(12):4396-403. PubMed ID: 11724851 [TBL] [Abstract][Full Text] [Related]
32. Bordetella pertussis, Finland and France. Caro V; Elomaa A; Brun D; Mertsola J; He Q; Guiso N Emerg Infect Dis; 2006 Jun; 12(6):987-9. PubMed ID: 16707058 [TBL] [Abstract][Full Text] [Related]
33. The new strategy for allele identification of the genes coding for pertussis toxin subunit S1 (ptx S1) and pertactin (prn) in Bordetella pertussis. Fiett J; Letowska I; Gniadkowski M; Hryniewicz W J Microbiol Methods; 2003 Dec; 55(3):651-66. PubMed ID: 14607408 [TBL] [Abstract][Full Text] [Related]
34. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. King AJ; Berbers G; van Oirschot HF; Hoogerhout P; Knipping K; Mooi FR Microbiology (Reading); 2001 Nov; 147(Pt 11):2885-95. PubMed ID: 11700340 [TBL] [Abstract][Full Text] [Related]
35. Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis. Mäkinen J; Mertsola J; Viljanen MK; Arvilommi H; He Q J Clin Microbiol; 2002 Jun; 40(6):2213-6. PubMed ID: 12037089 [TBL] [Abstract][Full Text] [Related]
36. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines. Hegerle N; Guiso N Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157 [TBL] [Abstract][Full Text] [Related]
37. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Fingermann M; Fernández J; Sisti F; Rodríguez ME; Gatti B; Bottero D; Graieb A; Gaillard ME; Ayala SG; Mooi FR; Lopardo H; Hozbor D Vaccine; 2006 Apr; 24(17):3513-21. PubMed ID: 16545509 [TBL] [Abstract][Full Text] [Related]
38. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Hausman SZ; Burns DL Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544 [TBL] [Abstract][Full Text] [Related]